Overview

Bioequivalence Study Between Two Oral Formulations of Naproxen 500 mg Tablets Under Fasting Conditions

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Compare the rate and extent of absorption of two oral formulations of Naproxen Tablets, administered as a 1 x 500 mg tablet under fasting conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Perrigo Company
Treatments:
Naproxen